Boston, Massachusetts and Cambridge, UK May 19, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components […]

Boston, Massachusetts and Cambridge, UK March 22, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, has been selected by NVIDIA to harness the power of  the UK’s most powerful supercomputer, Cambridge-1. Alchemab will use the NVIDIA DGX SuperPOD supercomputing cluster, […]

Boston, Massachusetts and Cambridge, UK March 7, 2022 – Alchemab Therapeutics – a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, has announced an extension of its collaboration with Medicines Discovery Catapult (MDC), a national facility enabling the UK’s community to accelerate innovative drug discovery. The collaboration […]